CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 119 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $674,176 | -28.8% | 30,883 | +3.7% | 0.00% | -33.3% |
| Q2 2023 | $946,865 | +40.4% | 29,785 | +7.7% | 0.01% | +50.0% |
| Q1 2023 | $674,359 | -21.1% | 27,649 | +2.0% | 0.00% | -33.3% |
| Q4 2022 | $854,702 | +17.2% | 27,099 | +5.0% | 0.01% | +20.0% |
| Q3 2022 | $729,000 | +8.3% | 25,800 | +1.4% | 0.01% | 0.0% |
| Q2 2022 | $673,000 | -4.9% | 25,435 | +25.8% | 0.01% | +25.0% |
| Q1 2022 | $708,000 | +0.9% | 20,226 | -6.6% | 0.00% | 0.0% |
| Q4 2021 | $702,000 | +8.5% | 21,649 | -1.3% | 0.00% | +33.3% |
| Q3 2021 | $647,000 | +27.9% | 21,939 | +11.0% | 0.00% | +50.0% |
| Q2 2021 | $506,000 | – | 19,759 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,713,470,000 | 41.39% |
| Perceptive Advisors | 6,511,727 | $184,021,000 | 5.34% |
| Finepoint Capital LP | 536,901 | $15,173,000 | 4.99% |
| Artal Group S.A. | 2,000,000 | $56,520,000 | 2.41% |
| Rock Springs Capital Management LP | 2,499,148 | $70,626,000 | 1.82% |
| Ikarian Capital, LLC | 178,100 | $5,033,000 | 1.00% |
| Hood River Capital Management LLC | 896,572 | $25,337,000 | 0.97% |
| Frazier Life Sciences Management, L.P. | 393,000 | $11,106,000 | 0.86% |
| HighVista Strategies LLC | 23,611 | $667,000 | 0.38% |
| FEDERATED HERMES, INC. | 3,313,333 | $93,635,000 | 0.27% |